<DOC>
	<DOCNO>NCT01714089</DOCNO>
	<brief_summary>The purpose study determine whether RNS60 effective treatment RR-MS compare interferon beta-1a .</brief_summary>
	<brief_title>Proof Concept Study Evaluating RNS60 Treatment Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Males female , age 18 50 year . 2 . Diagnosis RRMS accord McDonald 2010 diagnostic criterion prior brain MRI demonstrate lesion consistent RRMS , within past year . 3 . No evidence relapse 60 day prior enrollment . 4 . EDSS score 05 screening . 5 . Women childbearing potential negative pregnancy test ( serum HCG ) screening . 6 . Men woman reproductive potential commit use adequate contraception study 1 month follow last day treatment . 7 . Subjects must capable understand purpose risk study provide write , informed consent . 1 . Diagnosis Secondary Progressive MS , Primary Progressive MS Progressive Relapsing MS. 2 . Normal baseline brain MRI . 3 . History clinically significant autoimmune disease : inflammatory bowel disease , diabetes , lupus severe asthma . 4 . Current prior malignancy ( exclude nonmelanoma skin carcinoma situ carcinoma cervix adequately treat . ) 5 . Significant organ dysfunction , include cardiac , renal ( eGFR ≤ 60 ml/min . ) , liver , central nervous system , pulmonary , vascular , gastrointestinal , endocrine , metabolic ( e.g. , creatinine ≥ 1.6 mg/dL ; ALT AST ≥ 1.5x upper limit normal ) , history myocardial infarction , congestive heart failure , arrhythmia within 6 month prior enrollment . 6 . Steroid therapy within 60 day prior enrollment , exception corticosteroid ACTH relapse treatment course study . 7 . Known allergy GadoliniumDTPA 8 . Therapy immunomodulatory drug within 3 month prior enrollment , include limited interferon , glatiramir acetate , BG12 , teriflunomide , laquinimod IV immunoglobulin . 9 . Treatment time immunosuppressive drug cladribine , total lymphoid irradiation , monoclonal antibody treatment , mitoxantrone , Tysabri , fingolimod , cytoxan , methotrexate . 10 . Participation investigational therapy within one year prior enrollment , unless give approval PI . 11 . Known suspected current past alcohol drug abuse within one year prior enrollment . 12 . Any medical , psychiatric condition could result subject able comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Relapsing remit multiple sclerosis</keyword>
	<keyword>RR-MS</keyword>
</DOC>